Advertisement

American Journal of Clinical Dermatology

, Volume 6, Issue 2, pp 113–118 | Cite as

Efalizumab

  • Keri Wellington
  • Caroline M. Perry
Adis Drug Profile

Abstract

▴ Efalizumab is a humanized monoclonal antibody that binds to CD11a, the α-subunit of lymphocyte function-associated antigen-1, and consequently inhibits T-cell activation.

▴ In randomized, double-blind, placebo-controlled trials, efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks, significantly reduced disease activity in patients with chronic, moderate-to-severe plaque psoriasis. Significantly more efalizumab recipients had a ≥75% decrease in the Psoriasis Area and Severity Index (PASI) score [22.4–38.9%] than placebo recipients (2.4–4.9%); an additional 12 weeks of treatment resulted in sustained or increased PASI responses.

▴ The efficacy of weekly subcutaneous efalizumab was maintained during 15 months of treatment.

▴ Efalizumab significantly improved health-related quality of life in patients with chronic plaque psoriasis, with significant improvements in all the Dermatology Life Quality Index domains.

▴ Efalizumab was generally well tolerated in patients with chronic, moderate-to-severe plaque psoriasis, with few serious adverse events or treatment withdrawals. The most common adverse events were headache, chills, myalgia, pain, and fever; these most often occurred within 2 days of administration of the drug, were most frequent after the first or second dose, and decreased in frequency over time.

Keywords

Psoriasis Plaque Psoriasis Dermatology Life Quality Index Efalizumab Fluocinolone Acetonide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Cather JC, Cattier JC, Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther. 2003 Apr; 3 (2): 361–70PubMedCrossRefGoogle Scholar
  2. 2.
    Lebwohl M. Psoriasis. Lancet. 2003; 361: 1197–204PubMedCrossRefGoogle Scholar
  3. 3.
    Pariser DM. Management of moderate to severe plaque psoriasis with biologic therapy. Manag Care. 2003 Apr; 12 (4): 36–44PubMedGoogle Scholar
  4. 4.
    Agarwal R, Vij N, Katare OP. Biotherapy: a novel approach in the treatment of psoriasis. Drugs Future. 2002; 27 (11): 1071–7CrossRefGoogle Scholar
  5. 5.
    Sobell JM, Hallas SJ. Systemic therapies for psoriasis: understanding current and newly emerging therapies. Semin Cutan Med Surg. 2003; 22 (3): 187–95PubMedCrossRefGoogle Scholar
  6. 6.
    Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003 Aug; 49 (2 Suppl.): S98–104PubMedCrossRefGoogle Scholar
  7. 7.
    Prinz JC. The role of T cells in psoriasis. J Fur Acad Dermatol Venereol. 2003; 17 (3): 257–70CrossRefGoogle Scholar
  8. 8.
    Schön MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol. 2003; 121 (5): 951–62PubMedCrossRefGoogle Scholar
  9. 9.
    Bauer RJ, Dedrick RL, White ML, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm. 1999 Aug; 27 (4): 397–420PubMedGoogle Scholar
  10. 10.
    Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD1la antibody. Arch Dermatol. 2002 May; 138 (5): 591–600PubMedCrossRefGoogle Scholar
  11. 11.
    Werther WA, Gonzalez TA, O’Connonr SJ, et al. Humanization of an antilymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding rhesus LFA-1. J Immunol. 1996; 157 (11): 4986–95PubMedGoogle Scholar
  12. 12.
    Dedrick RL, Bauer R, Bohmann D, et al. Pharmacokinetics and pharmacodynamics of subcutaneously administered anti-CD11a (hu1124) in psoriasis subjects [abstract no. 505 plus poster]. 59th Annual Meeting American Academy of Dermatology; 2001 Mar 2–7; Washington (DC)Google Scholar
  13. 13.
    Gottlieb A, Krueger JG, Bright R, et al. Effects of administrations of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol. 2000 Mar; 42: 428–35PubMedCrossRefGoogle Scholar
  14. 14.
    Krueger J, Gottlieb A, Miller B, et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking [abstract no. HB9]. J Invest Dermatol. 2000 Aug; 115 (2): 333PubMedCrossRefGoogle Scholar
  15. 15.
    Genetech Inc. Raptiv™ (efalizumab): for injection, subcutaneous [online]. Available from URL: http://www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf [Accessed 2005 Feb 25]
  16. 16.
    Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005; 52 (3): 425–33PubMedCrossRefGoogle Scholar
  17. 17.
    Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290 (23): 3073–80PubMedCrossRefGoogle Scholar
  18. 18.
    Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003 Nov 20; 349 (21): 2004–13PubMedCrossRefGoogle Scholar
  19. 19.
    Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004 Nov; 3 (6): 614–24PubMedGoogle Scholar
  20. 20.
    Ashcroft DM, Wan Po AL, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141: 185–91PubMedCrossRefGoogle Scholar
  21. 21.
    Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141 (1): 31–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Adis International Inc.YardleyUSA

Personalised recommendations